SecBot SecBot
SECBOTREPLAY Home › Report › LGVN

LGVN · Longeveron reported a 50% year-over-year revenue decline for 2025,…

Longeveron · PRESS-RELEASE filed Mar 17, 2026 at 16:05 ET

At the news

BEARISHIMPACT 7/10

PRESS-RELEASE filed Mar 17, 2026 at 16:05 ET

Longeveron reported a 50% year-over-year revenue decline for 2025, driven by lower clinical trial and contract manufacturing demand, while net loss widened to $22.7 million. The company raised $15 million in a private placement, extending its cash runway into Q4 2026, and remains on track for pivotal Phase 2b HLHS trial results in Q3 2026. Despite positive clinical and regulatory developments, deteriorating financials dominate the near-term outlook.

  • 2025 revenue was $1.2 million, down 50% from $2.4 million in 2024
  • Net loss increased to $22.7 million in 2025 from $16.0 million in 2024
  • Cash and cash equivalents dropped to $4.7 million from $19.2 million in 2024
  • Raised $15 million in initial closing of a $30 million private placement led by Coastlands Capital and Janus Henderson

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access